Jazz Pharmaceuticals Q3 Earnings Call Highlights

Jazz Pharmaceuticals Q3 Earnings Call Highlights

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported record third-quarter revenue of $1.24 billion, up 10% from a year earlier, and raised its full-year 2026 revenue outlook as growth in its sleep and oncology businesses offset product-specific pressures and continued investment in its pipeline. Chief Execu

Vertex raises 2026 revenue guidance following mixed Q3 results

Vertex lifts 2026 revenue guidance after Q3 results. Read more here.

Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction

Vertex's cystic fibrosis business is still growing, but the company is pouring those gains into new franchises. Here's what the third quarter shows about the cost of building its next act.

Vertex Reports Third Quarter 2026 Financial Results

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2026, and raised its full year 2026 revenue guidance. “Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the more...

Vertex Pharmaceuticals Raises 2026 Revenue Guidance After Mixed Q3

The new range tops out below the $13.28 billion consensus estimate, as quarterly revenue beat estimates and the bottom-line result missed.

Vertex Continues Its Buy-Zone Run After Hiking 2026 Sales Guidance

Vertex stock rose late Monday on better-than-expected third-quarter sales and a guidance boost following its Crinetics close. The post Vertex Continues Its…